ClinicalTrials.gg

Program

rilogrotug

Also written as “AV-380” and “Rilogrotug”.

Its studies are mostly in Cachexia, led by LG Chem.

Furthest: phase 3, since Oct 15, 20263 company-led studies, 1 open or runningNext primary completion: Mar 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LG Chem31 open or runningphase 3since Oct 15, 2026Mar 8, 2021Mar 2030phase 3 · NCT07888075

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2021First study: phase 1 study in CachexiaFirst studyNCT04815551 · 51 enrolled · United States
  2. May 2, 2023Phase 1 study in CachexiaNCT05865535 · 24 enrolled · United States
  3. Oct 15, 2026Phase 3 study in CachexiaPhase 3 reachedNCT07888075 · 950 planned
  4. Oct 28, 2026Primary completion moved from 2028-10 to 2030-03Date moved laterphase 3 · +17 months · NCT07888075

Ahead

  1. Mar 2030Primary completion: phase 3 study in CachexiaNCT07888075

TargetBeta

GDF15 →PDF →read by rule
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1; MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming growth factor-beta; pTGFB; prostate-derived factor; ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
visugromabrulecatalym-gmbhphase 36

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07888075Cachexia3Not yet recruitingMar 2030950
NCT05865535Cachexia · United States1CompletedAug 11, 202624
NCT04815551Cachexia · United States1CompletedJan 14, 202251

How it is read

Names in the registry

  • “AV-380”, 2 entries
  • “Rilogrotug”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.